Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2026
Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft versus host disease
3 February 2026 - British Columbia and Ontario recently added Rezurock (belumosudil) to their provincial formularies for adult and pediatric patients ...
Posted by Michael Wonder on 30 Jan 2026
Canadians wait too long for access to innovative drugs, cautions the MEI
29 January 2026 - Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death ...
Posted by Michael Wonder on 30 Jan 2026
Government of Canada announces the new Chairperson of the Patented Medicine Prices Review Board
29 January 2026 - Today, the Honourable Marjorie Michel, Minister of Health, announced the designation of a new Chairperson for ...
Posted by Michael Wonder on 15 Jan 2026
Ontario pioneers access to treatment for severe alopecia areata with Lilly's Olumiant
14 January 2026 - Eli Lilly Canada announced today that Ontario leads the way as the first province to add Olumiant ...
Posted by Michael Wonder on 20 Dec 2025
Eli Lilly cuts price of diabetes, weight loss drugs in Canada
17 December 2025 - Eli Lilly is slashing the prices of its popular diabetes and weight loss drugs Mounjaro and ...
Posted by Michael Wonder on 09 Dec 2025
Saskatchewan adds Capvaxive to publicly funded adult immunisation program
8 December 2025 - Merck announced today that the province of Saskatchewan has added Capvaxive, a 21 valent pneumococcal conjugate vaccine, ...
Posted by Michael Wonder on 06 Dec 2025
New resource: understanding Canada’s drug approval and reimbursement pathway
3 December 2025 - Understanding how new oncology and non-oncology drugs move through Canada’s regulatory and drug access pathways can ...
Posted by Michael Wonder on 05 Dec 2025
New data on drug approvals and reimbursement recommendations in Canada
27 November 2025 - We have published new data about Canada’s pharmaceutical landscape, including data about drug submissions filed with ...
Posted by Michael Wonder on 21 Nov 2025
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Winrevair (sotatercept)
20 November 2025 - Merck announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for Winrevair (sotatercept). ...
Posted by Michael Wonder on 09 Nov 2025
Rhythm Pharmaceuticals announces public reimbursement for Imcivree (setmelanotide) in Canada in five provinces and under the Federal Non-Insured Health Benefits Program
5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, ...
Posted by Michael Wonder on 07 Nov 2025
Rezurock now covered in Quebec for people living with chronic graft versus host disease
6 November 2025 - Sanofi is pleased to announce that Quebec has added Rezurock (belumosudil tablets) to the list of medications ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 19 Sep 2025
Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases
18 September 2025 - -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 16 Sep 2025
AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta
15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...